Institutional Owners May Take Dramatic Actions as Sutro Biopharma, Inc.'s (NASDAQ:STRO) Recent 17% Drop Adds to One-year Losses
Institutional Owners May Take Dramatic Actions as Sutro Biopharma, Inc.'s (NASDAQ:STRO) Recent 17% Drop Adds to One-year Losses
Key Insights
主要见解
- Given the large stake in the stock by institutions, Sutro Biopharma's stock price might be vulnerable to their trading decisions
- A total of 13 investors have a majority stake in the company with 50% ownership
- Ownership research along with analyst forecasts data help provide a good understanding of opportunities in a stock
- 由于机构股东持有Sutro Biopharma的大量股份,该公司股价可能受到他们交易决策的影响。
- 共有13个投资者拥有该公司的大多数股份,持股比例为50%。
- 所有权研究和分析师预测数据有助于更好地了解股票市场的机会。
If you want to know who really controls Sutro Biopharma, Inc. (NASDAQ:STRO), then you'll have to look at the makeup of its share registry. We can see that institutions own the lion's share in the company with 47% ownership. That is, the group stands to benefit the most if the stock rises (or lose the most if there is a downturn).
如果您想知道谁真正控制着Sutro Biopharma公司(NASDAQ: STRO),那么您需要查看其股份登记簿的构成。我们可以看到,机构拥有该公司47%的所有权。也就是说,如果股票上涨,该组将受益最多(如果出现衰退,则损失最大)。
And so it follows that institutional investors was the group most impacted after the company's market cap fell to US$283m last week after a 17% drop in the share price. Needless to say, the recent loss which further adds to the one-year loss to shareholders of 37% might not go down well especially with this category of shareholders. Often called "market movers", institutions wield significant power in influencing the price dynamics of any stock. As a result, if the downtrend continues, institutions may face pressures to sell Sutro Biopharma, which might have negative implications on individual investors.
公司市值上周下跌了17%,跌至2.83亿美元,因此机构投资者成为最受影响的群体。不用说,最近的亏损使股东的一年内损失达到37%,尤其是对这类股东来说,该亏损可能不利。通常被称为“市场推动者”的机构对任何股票的价格动态产生重大影响力。因此,如果下降趋势持续,机构可能面临售出Sutro Biopharma的压力,这可能对个人投资者产生负面影响。
Let's delve deeper into each type of owner of Sutro Biopharma, beginning with the chart below.
让我们深入探讨Sutro Biopharma的每种所有者类型,从下面的图表入手。
![ownership-breakdown](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240618/0-23866fbe4688636b6211eed2031965be-0-f4fdc32b77022d2e43f431109077b828.png/big)
What Does The Institutional Ownership Tell Us About Sutro Biopharma?
机构股东分布揭示了Sutro Biopharma的哪些信息?
Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.
机构投资者通常将自己的回报与常见的指数回报进行比较。因此,他们通常会考虑购买包括在相关基准指数中的较大公司。
Sutro Biopharma already has institutions on the share registry. Indeed, they own a respectable stake in the company. This suggests some credibility amongst professional investors. But we can't rely on that fact alone since institutions make bad investments sometimes, just like everyone does. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Sutro Biopharma's earnings history below. Of course, the future is what really matters.
Sutro Biopharma已经在股份登记簿上注册了机构。事实上,他们在公司中拥有可观的股份。这表明在专业投资者中具有一定的信誉。但是我们不能仅依靠这个事实,因为机构有时会犯错误的投资,就像每个人都会一样。如果多个机构同时改变他们对一个股票的看法,你会看到股票价格快速下跌。因此,值得看一下下面的Sutro Biopharma收益历史。当然,未来才是真正重要的。
![earnings-and-revenue-growth](https://usnewsfile.moomoo.com/public/MM-PersistNewsContentImage/7781/20240618/0-23866fbe4688636b6211eed2031965be-1-46b8d7a936050e78152fc8d3673ab858.png/big)
Our data indicates that hedge funds own 25% of Sutro Biopharma. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. The company's largest shareholder is Point72 Asset Management, L.P., with ownership of 7.3%. In comparison, the second and third largest shareholders hold about 7.1% and 7.0% of the stock.
经过更多的挖掘,我们发现前13名股东在公司中拥有50%的股权,表明没有单一股东对该公司具有重大控制权。
After doing some more digging, we found that the top 13 have the combined ownership of 50% in the company, suggesting that no single shareholder has significant control over the company.
通过股权调查,我们发现前13名股东在公司中拥有50%的股权,表明没有单一股东对该公司具有重大控制权。
While it makes sense to study institutional ownership data for a company, it also makes sense to study analyst sentiments to know which way the wind is blowing. There are a reasonable number of analysts covering the stock, so it might be useful to find out their aggregate view on the future.
虽然仔细研究公司的机构持股数据是有意义的,但研究分析师对该股票的看法也是有意义的。有相当数量的分析师在跟踪该股票,因此了解他们对于未来发展的总体看法可能会有所帮助。
Insider Ownership Of Sutro Biopharma
Sutro Biopharma的内部股东持股情况。该公司的市值仅为2.83亿美元,上市公司高管和内部人员持有约300万美元的股票。一些人会说,这显示了股东与管理层之间的契合度。但是值得检查一下这些内部人员是否一直在卖出股票。
While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders. Management ultimately answers to the board. However, it is not uncommon for managers to be executive board members, especially if they are a founder or the CEO.
虽然内部人士的精确定义可能是主观的,几乎每个人都认为董事会成员是内部人士。管理层最终向董事会负责。但是,如果他们是创始人或CEO,经理成为执行董事会成员并不罕见。
Insider ownership is positive when it signals leadership are thinking like the true owners of the company. However, high insider ownership can also give immense power to a small group within the company. This can be negative in some circumstances.
当内部人持股情况表明领导层思考和公司真正所有者一样时,内部所有权是积极的。然而,高达内部人士所有权也可能为公司内的小团体带来巨大的权力。在某些情况下,这可能是负面的。
We can see that insiders own shares in Sutro Biopharma, Inc.. It has a market capitalization of just US$283m, and insiders have US$3.0m worth of shares, in their own names. Some would say this shows alignment of interests between shareholders and the board. But it might be worth checking if those insiders have been selling.
通常,谁持有Sutro Biopharma的股票?
General Public Ownership
一般大众所有权
The general public, who are usually individual investors, hold a 27% stake in Sutro Biopharma. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.
普通公众,通常是个人投资者,持有Sutro Biopharma的27%的股份。尽管这种所有权具有说服力,无法在自己的利益中左右政策决策,但他们仍然可以对公司政策产生集体影响。
Next Steps:
下一步:
It's always worth thinking about the different groups who own shares in a company. But to understand Sutro Biopharma better, we need to consider many other factors. For example, we've discovered 3 warning signs for Sutro Biopharma that you should be aware of before investing here.
了解一个公司中股东的不同群体总是有价值的。但是,要更好地了解Sutro Biopharma,我们需要考虑许多其他因素。例如,我们在此之前已经发现了3个Sutro Biopharma的预警标示,您在此前进行投资时需要注意这些标示。
If you are like me, you may want to think about whether this company will grow or shrink. Luckily, you can check this free report showing analyst forecasts for its future.
如果您像我一样,可能希望考虑这家公司是否会增长或缩小。幸运的是,您可以查看此免费报告,显示分析师对其未来的预测。
NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.
注:本文中的数据是使用最后一个财务报表日期结束的为期12个月的数据计算的。这可能与全年年度报告数据不一致。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者,发送电子邮件至editorial-team (at) simplywallst.com。
这篇文章是Simply Wall St的一般性文章。我们根据历史数据和分析师预测提供评论,只使用公正的方法论,我们的文章并不意味着提供任何金融建议。文章不构成买卖任何股票的建议,也不考虑您的目标或您的财务状况。我们的目标是带给您基本数据驱动的长期关注分析。请注意,我们的分析可能不考虑最新的价格敏感公司公告或定性材料。Simply Wall St没有任何股票头寸。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
对本文有反馈?关于内容有所顾虑?直接和我们联系。或者发送电子邮件至editorial-team@simplywallst.com。